Protective Influence of SGLT-2 Inhibitors Against Heart Failure in Type 2 Diabetes Mellitus Through Longitudinal Clinical Database Analysis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Dec 17

PMID 39685552

Authors

Attila Csaba Nagy

Agnes Toth

Natalia Bak

Battamir Ulambayar

Amr Sayed Ghanem

Ferenc Sztanek

Affiliations

Soon will be listed here.

Abstract

: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, initially designed for type 2 diabetes, promote glucose excretion and lower blood glucose. Newer analogs like empagliflozin and dapagliflozin improve cardiovascular outcomes through mechanisms other than glycemic control, including blood pressure reduction and anti-inflammatory effects. Given the high cardiovascular risk present in diabetes, our study aims to emphasize the cardioprotective benefits of SGLT-2 inhibitors as a preventive therapy for heart failure (HF) in high-risk T2DM patients. : Using data from 2542 patients identified by the ICD-10 E11 code from 2016 to 2020, this longitudinal study excluded those with E10 codes or those undergoing insulin treatment to focus on non-insulin-dependent T2DM. a multiple logistic regression model assessed HF incidence while adjusting for demographics and HbA1c. : SGLT-2 inhibitor use significantly lowered the odds of heart failure events (OR = 0.55, 95% CI: 0.31-0.99, = 0.046), with a significant difference by gender (OR = 0.45, 95% CI: 0.28-0.71, = 0.001) and eGFR (OR = 0.98, 95% CI: 0.97-0.99, = 0.004). : The real-world data highlight SGLT-2 inhibitors as promising for HF prevention and broader cardiometabolic health in T2DM, with potential value in managing complex comorbid profiles.

References

Blaschek W . Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors. Planta Med. 2017; 83(12-13):985-993. DOI: 10.1055/s-0043-106050. View

Garla V, Butler J, Lien L . SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. Curr Cardiol Rep. 2021; 23(6):59. DOI: 10.1007/s11886-021-01486-3. View

Jin Q, Lau E, Luk A, Tam C, Ozaki R, Lim C . Circulating metabolomic markers linking diabetic kidney disease and incident cardiovascular disease in type 2 diabetes: analyses from the Hong Kong Diabetes Biobank. Diabetologia. 2024; 67(5):837-849. PMC: 10954952. DOI: 10.1007/s00125-024-06108-5. View

Chao E, Henry R . SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9(7):551-9. DOI: 10.1038/nrd3180. View

Caruso I, Giorgino F . SGLT-2 inhibitors as cardio-renal protective agents. Metabolism. 2021; 127:154937. DOI: 10.1016/j.metabol.2021.154937. View

Lee C, Auld J . Heart Failure: A Primer. Crit Care Nurs Clin North Am. 2015; 27(4):413-25. DOI: 10.1016/j.cnc.2015.07.009. View

Lambers Heerspink H, de Zeeuw D, Wie L, Leslie B, List J . Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013; 15(9):853-62. PMC: 3906841. DOI: 10.1111/dom.12127. View

Salvatore T, Carbonara O, Cozzolino D, Torella R, Nasti R, Lascar N . Kidney in diabetes: from organ damage target to therapeutic target. Curr Drug Metab. 2011; 12(7):658-66. DOI: 10.2174/138920011796504509. View

Ehrenkranz J, Lewis N, Kahn C, Roth J . Phlorizin: a review. Diabetes Metab Res Rev. 2004; 21(1):31-8. DOI: 10.1002/dmrr.532. View

10.

Li Z, Yuan Y, Qi Q, Wang Q, Feng L . Relationship between dyslipidemia and diabetic retinopathy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Syst Rev. 2023; 12(1):148. PMC: 10463379. DOI: 10.1186/s13643-023-02321-2. View

11.

Fadini G, Spinetti G, Santopaolo M, Madeddu P . Impaired Regeneration Contributes to Poor Outcomes in Diabetic Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2019; 40(1):34-44. DOI: 10.1161/ATVBAHA.119.312863. View

12.

Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley J . Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2011; 1(2):57-92. PMC: 3138482. DOI: 10.1007/s13300-010-0006-4. View

13.

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

14.

Gager G, von Lewinski D, Sourij H, Jilma B, Eyileten C, Filipiak K . Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. Biomed Pharmacother. 2021; 143:112169. DOI: 10.1016/j.biopha.2021.112169. View

15.

Behzad H, Asham H, Beheshtirouy S, Mashayekhi S, Jafari N, Entezari-Maleki T . Sodium-glucose cotransporter-2 inhibitors in individuals with ischemia reperfusion injury: A systematic review. Perfusion. 2024; :2676591241257371. DOI: 10.1177/02676591241257371. View

16.

OHara D, Lam C, McMurray J, Yi T, Hocking S, Dawson J . Applications of SGLT2 inhibitors beyond glycaemic control. Nat Rev Nephrol. 2024; 20(8):513-529. DOI: 10.1038/s41581-024-00836-y. View

17.

Lytvyn Y, Perkins B, Cherney D . Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes. 2015; 39(3):239-46. DOI: 10.1016/j.jcjd.2014.10.013. View

18.

Palazzuoli A, Iacoviello M . Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev. 2022; 28(3):585-596. PMC: 10140137. DOI: 10.1007/s10741-022-10238-6. View

19.

Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S . The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity (Silver Spring). 2017; 26(1):70-80. DOI: 10.1002/oby.22066. View

20.

Gamrat A, Surdacki M, Chyrchel B, Surdacki A . Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis. J Clin Med. 2020; 9(7). PMC: 7408687. DOI: 10.3390/jcm9072090. View